About IQVIA Indonesia

We are IQVIA, The Human Data Science Company

Healthcare is an industry designed to help humans. As a global community, we continuously invest and commit to advancing human health. To deliver value and real outcomes. To rise to the challenge to find the next breakthrough by making the most of increasingly limited resources.

We are inspired by the potential and propelled by the possibilities. We share the vision to drive healthcare forward. To see how we can help accelerate progress and achievements. Others are developing these medical breakthroughs. We do our part by using breakthroughs in insights, technology and human intelligence to reimagine and deliver ways to help make them a reality.

It’s bigger than better clinical trials. Or advances in technologies and analytics. Or faster insights. It’s about unleashing the power of human data science. And that is why IMS Health and Quintiles have come together to be IQVIA, The Human Data Science Company.

Motivated by the industry we help, we’re committed to providing solutions that enable life sciences companies to innovate with confidence, maximize opportunities, and, ultimately, drive human health outcomes forward.

Driving Healthcare Performance in Indonesia

Established in 1990, IQVIA Indonesia offers a broad range of clinical and commercial services and solutions. Our commercial services started with market data and expanded into market research. We recently launched new audits aligned to current market dynamics.

We offer a full range of development services, including clinical monitoring, patient recruitment, site management, quality management and medical services. Our staff includes experienced clinical trial monitors from a range of backgrounds, including medical doctors, pharmacists and bio-medical scientists.

Indonesia Healthcare Outlook

Since the launch of Indonesia's Universal Health Coverage (UHC) program in 2014, about 180 million people have enrolled - almost 70 percent of the country's total population of 259 million. By 2019, UHC enrollment is forecast to reach 100 percent. Indonesia’s private insurance penetration is estimated at 8 percent, or 20 million people. UHC could drive the demand for inpatient and outpatient services at public hospitals and also among participating private hospitals as more patients have access to healthcare.

Indonesia’s growing economy is expanding the middle class. Both rising incomes and the UHC program are expected to accelerate private sector investment in healthcare.

Primary health care is the front line of the UHC program administered by the Ministry of Health. Patient volume is expected to increase significantly between now and 2019. Despite improvements at government-owned hospitals, the increased volume is expected to result in longer waits for patients. Those with private insurance or the ability to pay out-of-pocket can expect shorter wait periods; those with the need for specialist doctors will likely go to private hospitals.

Biopharmaceutical Market Overview

The generic segment remains the most attractive. Local and multinational drug manufacturers are expecting consumption to continue to increase as a result of UHC-driven demand from government-run and participating private hospitals. Indonesia accounts for the highest proportion of ASEAN over-the-counter (OTC) medicine sales, 40 percent, indicating the propensity of domestic consumers for self-medication. OTC manufacturers can expect growing demand during the medium to long terms.

Middle-class Indonesian consumers increasingly prefer branded generics to lower-cost, unbranded drugs, creating opportunities for generic manufacturers and importers. With the increase access to healthcare through UHC and economic improvement, people are likely to move away from self-treatment to seek treatment in clinic and hospitals.

To meet the growing demand, the Indonesian government has been pushing for self-sufficient drug production and opening the pharmaceutical industry to foreign investment. The Indonesian government intends to address major health condition by obtaining more affordable drugs in area of oncology, cardiovascular, diabetes and infectious disease by way of using biosimilar product and vaccine. Improving clinical trial capability is one way to answer the country’s need for more innovative healthcare solutions to address these needs.

Regulatory Environment for Clinical Development

The government is supporting efforts to transform Indonesia's biopharmaceutical and medical device industry from its focus on manufacturing/production to be more R&D- and innovation-based. Early engagement with local regulatory authorities is essential for success in clinical development programs that include Indonesia.

There are types of research that does not require regulatory authority approval, such as disease or product registry studies; health economic and outcomes research; and local data generation for regulatory and marketing purposes. These types of research are still very much needed in the country to drive public health policies.

Among recent significant regulatory changes are:

  • Presidential Instruction No. 6 year 2016 (re-emphasized by the Ministry of Health Decree No. 17 in 2017) provides direction for the biopharma and medical devices to support improvement in health services under UHC.
  • Head of National Agency of Drug and Food Control Decree No. 21 (2015) regulating clinical trial conduct for pre- and post-marketing (phase I to IV) studies inclusive of vaccine development guidelines.
  • Head of National Agency of Drug and Food Control Decree No. 16 (2015) regulates new drug development and manufacturing by local and foreign research institutions or the pharmaceutical industry.
  • Head of National Agency of Drug and Food Control Decree No. 17 (2015) provides guidance for research and development of biosimilars.

Disease Prevalence

Non-communicable diseases (NCDs) account for about two-thirds of all deaths in Indonesia. The four major NCDs are cardiovascular diseases, diabetes, cancers, and chronic respiratory diseases. Significant communicable diseases are tuberculosis, HIV/AIDS, diarrhoea, malaria, pneumonia, hepatitis and tropical diseases such as rabies, leprosy, filariasis, leptospirosis, anthrax, yaws. All these remain on the government’s strategic health agenda.

Commercial Solutions

  • Information: Sales Audit and Prescription Audit 
  • Primary Market Research: Market Assessment, Brand Tracking and Customer Satisfaction 
  • Analytics: Segmentation & Targeting, Sales Force Size & Structure, Territory Alignment and Incentive Compensation

Clinical Research Experience & Services

We have strong experience in infectious diseases, respiratory, cardiovascular and metabolic diseases, psychiatry, and rheumatology. Our experiences range from early phase development to observational and Phase 4 studies, including Real-World Insights, and have specialized offerings for Investigator-Initiated Trials (IIT).